Editas Medicine (EDIT) Stock Price, Quote & News

Company Profile

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in No...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 401 9000

Website: www.editasmedicine.com

Address:

11 Hurley Street, Cambridge, United States

NVDAMillionaire Feb. 4 at 9:27 AM

$EDIT Great piece that accurately captures EDIT's current position. So if you want to refresh your understanding of EDIT or learn about EDIT for the first time, this is essential reading. https://everyticker.com/quote/EDIT/analysis/editas-medicine-pivoting-to-in-vivo-fueled-by-differentiated-tech-and-extended-runway-edit

1 · Reply

Whoami1989 Feb. 3 at 5:28 PM

$EDIT pumpers - why are you so quiet ? common lets pump this harder. i am so fed up and want you to pump this hard

0 · Reply

harryvanluik Feb. 3 at 4:22 PM

$EDIT just for fun: suppose they have done some human trials and the outcome confirmes the very positive findings we are reading from already... What will that do to this PPS? By the way: Big pharma must be shitting their pants if EDIT will indeed have positive human trials: in that case Big Pharma will loose a huge part of their market.

0 · Reply

0x126 Feb. 3 at 3:51 PM

$EDIT need human trials next. Platform and technology was already, fast track would be the way.

0 · Reply

Whoami1989 Feb. 2 at 8:46 PM

$EDIT where are the pumpers? i need you to pump

0 · Reply

Kukc Feb. 2 at 3:52 PM

$EDIT on 🚨 let’s see

0 · Reply

StockBraker Jan. 31 at 1:06 PM

$EDIT https://tradersunion.com/news/companies/show/1360495-editas-ldl-breakthrough/

0 · Reply

DoctrBenway Jan. 30 at 3:10 PM

$EDIT Make that 22.5%😁

0 · Reply

DoctrBenway Jan. 30 at 3:05 PM

$EDIT Added another 15%

0 · Reply

Robert_Dempster Jan. 30 at 3:03 PM

$EDIT buying opportunity time to load and go long📢🐂

0 · Reply

Genflow Biosciences PLC Announces Directorate Change

Nov 10, 2025, 7:00 AM EST - 3 months ago

Editas Medicine Announces Third Quarter 2025 Results and Business Updates

Nov 3, 2025, 9:00 AM EST - 3 months ago

Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025

Oct 14, 2025, 6:18 PM EDT - 4 months ago

Editas Medicine: Three Strikes And It's Out, Or Third Time's The Charm?

Oct 9, 2025, 11:01 AM EDT - 4 months ago

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress

Oct 6, 2025, 9:00 AM EDT - 4 months ago

Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences

Sep 2, 2025, 11:14 AM EDT - 5 months ago

Editas Medicine, Inc. - Special Call

Sep 2, 2025, 7:00 AM EDT - 5 months ago

Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate

Aug 28, 2025, 4:01 PM EDT - 5 months ago

Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate

Aug 27, 2025, 9:00 AM EDT - 5 months ago

Editas Medicine to Participate in Upcoming Investor Conferences

Aug 12, 2025, 4:01 PM EDT - 6 months ago

Editas Medicine Announces Second Quarter 2025 Results and Business Updates

Jun 12, 2025, 2:01 AM EDT - 8 months ago

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June

May 20, 2025, 5:47 AM EDT - 9 months ago

I Missed The Quantum Rally - I Won't Miss The Next One

AMSC AUTL CAPR CLPT NTLA VANI VERV

May 14, 2025, 2:17 PM EDT - 9 months ago

Editas Medicine, Inc. (EDIT) BofA Securities 2025 Healthcare Conference (Transcript)

May 14, 2025, 9:31 AM EDT - 9 months ago

Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June

May 14, 2025, 7:01 AM EDT - 9 months ago

Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting

May 13, 2025, 7:01 AM EDT - 9 months ago

Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting

May 12, 2025, 4:30 PM EDT - 9 months ago

Editas Medicine Announces First Quarter 2025 Results and Business Updates

May 12, 2025, 4:01 PM EDT - 9 months ago

Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board

May 5, 2025, 4:01 PM EDT - 9 months ago

Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May

Apr 28, 2025, 4:31 PM EDT - 10 months ago

Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

Mar 20, 2025, 4:01 PM EDT - 11 months ago

Editas Medicine Announces Chief Financial Officer Transition

Mar 11, 2025, 4:07 PM EDT - 11 months ago

Editas Medicine, Inc. (EDIT) Barclays 27th Annual Global Healthcare Conference (Transcript)

Mar 10, 2025, 12:19 PM EDT - 11 months ago

Editas Medicine, Inc. (EDIT) Leerink Partners Global Healthcare Conference (Transcript)

Mar 5, 2025, 4:05 PM EST - 11 months ago

Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates

Mar 3, 2025, 5:01 PM EST - 1 year ago

Editas Medicine, Inc. (EDIT) TD Cowen 45th Annual Health Care Conference Transcript

Feb 24, 2025, 9:00 AM EST - 1 year ago

Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March

Jan 17, 2025, 12:20 PM EST - 1 year ago

Editas And Intellia: Strategic Shifts And Long-Term Investment Potential

NTLA

Jan 15, 2025, 4:35 PM EST - 1 year ago

Editas Medicine, Inc. (EDIT) 43rd Annual JPMorgan Healthcare Conference - (Transcript)

Jan 13, 2025, 9:00 AM EST - 1 year ago

Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

Jan 6, 2025, 9:00 AM EST - 1 year ago

Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 13, 2024, 6:44 AM EST - 1 year ago

Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026

Dec 12, 2024, 6:03 PM EST - 1 year ago

Editas to reduce about 65% of its workforce over the next six months

Dec 12, 2024, 4:00 PM EST - 1 year ago

Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

Dec 9, 2024, 12:00 PM EST - 1 year ago

Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting

Dec 3, 2024, 10:52 PM EST - 1 year ago

Editas Medicine, Inc. (EDIT) 7th Annual Evercore HealthCONx Conference (Transcript)

Nov 25, 2024, 12:59 PM EST - 1 year ago

Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts

Nov 19, 2024, 7:53 PM EST - 1 year ago

Editas Medicine, Inc. (EDIT) Presents at Stifel 2024 Healthcare Conference (Transcript)

Nov 4, 2024, 7:30 AM EST - 1 year ago

Editas Medicine Announces Third Quarter 2024 Results and Business Updates

Oct 22, 2024, 11:45 AM EDT - 1 year ago

Editas Medicine, Inc. (EDIT) Strategic Update Call Transcript

Oct 21, 2024, 4:30 PM EDT - 1 year ago

Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics

Oct 18, 2024, 4:01 PM EDT - 1 year ago

Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept

Oct 7, 2024, 3:33 PM EDT - 1 year ago

Editas Medicine (EDIT) Shares Plunge Amid Biotech Sector Fluctuations

Oct 6, 2024, 2:00 PM EDT - 1 year ago

Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma

AMGN BIIB BLUE BMY CRSP EXAS NTLA

Oct 3, 2024, 6:00 PM EDT - 1 year ago

Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust

Oct 1, 2024, 7:53 PM EDT - 1 year ago

Editas Medicine, Inc. (EDIT) Chardan's 8th Annual Genetic Medicines Conference (Transcript)

Sep 25, 2024, 11:46 AM EDT - 1 year ago

Editas Medicine: A Risk/Reward Worth Considering

Sep 17, 2024, 5:26 PM EDT - 1 year ago

Editas Medicine, Inc. (EDIT) 2024 Cantor Global Healthcare Conference (Transcript)

Sep 5, 2024, 11:19 PM EDT - 1 year ago

Editas Medicine, Inc. (EDIT) Presents at Wells Fargo 2024 Healthcare Conference (Transcript)

Sep 4, 2024, 7:17 PM EDT - 1 year ago

Editas Medicine, Inc. (EDIT) Presents at Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)

NVDAMillionaire Feb. 4 at 9:27 AM

1 · Reply

Whoami1989 Feb. 3 at 5:28 PM

$EDIT pumpers - why are you so quiet ? common lets pump this harder. i am so fed up and want you to pump this hard

0 · Reply

harryvanluik Feb. 3 at 4:22 PM

0 · Reply

0x126 Feb. 3 at 3:51 PM

$EDIT need human trials next. Platform and technology was already, fast track would be the way.

0 · Reply

Whoami1989 Feb. 2 at 8:46 PM

$EDIT where are the pumpers? i need you to pump

0 · Reply

Kukc Feb. 2 at 3:52 PM

$EDIT on 🚨 let’s see

0 · Reply

StockBraker Jan. 31 at 1:06 PM

$EDIT https://tradersunion.com/news/companies/show/1360495-editas-ldl-breakthrough/

0 · Reply

DoctrBenway Jan. 30 at 3:10 PM

$EDIT Make that 22.5%😁

0 · Reply

DoctrBenway Jan. 30 at 3:05 PM

$EDIT Added another 15%

0 · Reply

Robert_Dempster Jan. 30 at 3:03 PM

$EDIT buying opportunity time to load and go long📢🐂

0 · Reply

None_ Jan. 29 at 12:10 AM

$SGMO We know $EDIT is actively researching large serine recombinases as part of its platform efforts. The goal of this work is to expand the types of edits they can make in vivo (beyond CRISPR nucleases), to include knocking in entire genes (similar in concept to what recombinase platforms like Sangamo's MINT and Seamless aim for).

1 · Reply

Erminiottone Jan. 28 at 3:24 PM

$EDIT Haahahha this is going penny soon I will short up to 0.2 ! say hello to your bag keyboard scientistists!

3 · Reply

0x126 Jan. 28 at 3:01 PM

$EDIT waiting again for magnitude to be unblocked ($NTLA) damn

0 · Reply

Whoami1989 Jan. 27 at 8:56 PM

$EDIT simply put !!! the worst fpos

2 · Reply

harryvanluik Jan. 27 at 2:45 PM

$EDIT We are next!!! get ready to fly!!!!! NTLA | Intellia Therapeutics Inc. Intellia Therapeutics is trending after the FDA lifted the clinical hold on its MAGNITUDE-2 Phase 3 trial for ATTRv-PN, allowing patient enrollment to restart. The update has boosted investor confidence, with many pointing to the stock’s high short interest as a potential setup for a short squeeze. This development is also being seen as a strong positive signal for the broader gene-editing space.

0 · Reply

0x126 Jan. 27 at 1:54 PM

$EDIT I will not buy more if $NTLA breaks 20 and I sell for 70% gains

0 · Reply

0x126 Jan. 27 at 1:48 PM

$NTLA $EDIT guys from editas, last chance to hop on before bak to 20+

1 · Reply

Whoami1989 Jan. 26 at 9:00 PM

$EDIT The shittiest of all shits

0 · Reply

Whoami1989 Jan. 26 at 8:00 PM

$EDIT Dear idiotic pumpers - i hope that you will be very poor one day

0 · Reply

Robby83 Jan. 26 at 5:27 PM

$EDIT holy bear bot!!! 🤣 Just watching for another setup, looks 50/50.

0 · Reply

Whoami1989 Jan. 26 at 4:30 PM

$EDIT where are idiotic pumpers

0 · Reply

Whoami1989 Jan. 26 at 3:03 PM

$EDIT any doubt? it is not a fpos any more instead a mf fpos.

0 · Reply

Market Cap	194.26M
Revenue (ttm)	32.31M
Net Income (ttm)	-237.09M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-733.80%
Debt to Equity Ratio	0.00

Volume	1,633,600
Avg Vol	1,782,646
Day's Range	N/A - N/A
Shares Out	97.62M
Stochastic %K	27%
Beta	2.16
Analysts	Sell
Price Target	$4.91